Kalshi has launched prediction markets allowing traders to take positions on the outcomes of late-stage clinical trials and decisions by the U.S. Food and Drug Administration. The pilot program was developed with AppliedXL, a public intelligence company that monitors pharmaceutical data and analyzes clinical trial outcomes.
The markets are intended to produce publicly visible probabilities for whether a drug will achieve its primary clinical endpoint or receive a particular FDA decision.
Rather than investing in an entire pharmaceutical company, participants can express a view on the success or failure of an individual drug program.
A biotechnology company’s stock price may be affected by factors including its management, cash position, broader drug pipeline and market conditions.
Kalshi’s contracts are structured around a specific scientific or regulatory event, separating that outcome from the performance of the wider company.
The pilot will initially cover late-stage trials, which generally have more clearly defined endpoints and more publicly available information than early-stage studies.
Kalshi and AppliedXL will only list a clinical trial contract after enrollment in the underlying study has been completed.
This restriction is intended to reduce the risk that visible market probabilities could influence patient recruitment or physician referrals while a trial is still enrolling participants.
Every contract will identify a specific public document that determines how the market is resolved.
Potential resolution sources include the trial’s registered primary endpoint on ClinicalTrials.gov, an FDA approval letter or the voting record of an FDA advisory committee.
AppliedXL will establish the criteria for interpreting the document before trading begins.
Defining the rules in advance is intended to prevent the resolution standard from changing after clinical results or regulatory decisions become available.
AppliedXL will evaluate the relevant public documents and determine whether the stated conditions of each contract have been satisfied.
The process is designed to rely on primary regulatory and clinical records rather than promotional statements from drug developers or subjective analyst interpretations.
More than a dozen FDA-related contracts were included in the initial launch.
One market addresses whether the FDA will approve anito-cel, an experimental multiple myeloma treatment being developed by Gilead Sciences and Arcellx.
Another covers the potential approval of Summit Therapeutics’ ivonescimab, an experimental treatment for lung cancer.
Participants can also trade on whether AR1001, an experimental Alzheimer’s disease treatment from AriBio, will meet the primary endpoint of its late-stage POLARIS-AD trial.
Kalshi believes the markets could make information about drug development more accessible to investors, clinicians, patients and smaller biotechnology companies.
Probability estimates for clinical and regulatory success are frequently developed internally by pharmaceutical companies, investment banks and specialized research firms.
Prediction markets provide a continuously changing price based on the collective trading activity of participants evaluating publicly available evidence.
The resulting price can be interpreted as the market’s current probability for the specified outcome, although it does not guarantee that the event will occur.
Clinical trial prediction markets also introduce risks involving confidential information, market manipulation and potential conflicts of interest.
Kalshi will require employment verification from every person trading in the pilot markets.
Individuals possessing material nonpublic information about the drug, clinical trial or regulatory process will be prohibited from trading.
The company plans to examine trading behavior and market performance during the pilot before determining whether to introduce a broader range of biotechnology contracts.
Kalshi has also established terms for binary FDA decision contracts, including rules addressing approval outcomes, refuse-to-file decisions and extensions of regulatory deadlines.
The biotechnology initiative expands Kalshi beyond markets tied to areas such as elections, sports and weather.
The rollout could create a new source of real-time sentiment around individual drug candidates while giving traders a direct way to take positions on clinical and regulatory outcomes.
